Skip to main
BCAX

BCAX Stock Forecast & Price Target

BCAX Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Bicara Therapeutics Inc. is positioned favorably due to its innovative bifunctional therapy, ficera, which potentially captures approximately 30% of the eligible head and neck squamous cell carcinoma (HNSCC) market, underscoring its strong clinical relevance and projected revenue opportunities. The company has demonstrated improved clinical outcomes, with a raised probability of success to 65% for ficera in HNSCC, bolstered by promising data from parallel developments in the market. Additionally, the adaptive dosing strategy showcases biological efficacy that could accelerate approval timelines, further enhancing Bicara's competitive edge in the biopharmaceutical landscape.

Bears say

Bicara Therapeutics Inc faces a negative outlook primarily due to underwhelming clinical results for its lead program, ficera, which has led to a reduced probability of success and a decline in investor confidence regarding its application in head and neck squamous cell carcinoma (HNSCC) at only 30%. Furthermore, the lack of differentiated clinical data and the potential approval of competitive therapies may significantly hinder the sales potential of the company's products. Additionally, with the increasing immunity from HPV vaccinations expected to reduce rates of HPV-attributable HNSCC over time, the overall prognosis for treating various subtypes of the disease remains unfavorable.

BCAX has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicara Therapeutics Inc (BCAX) Forecast

Analysts have given BCAX a Buy based on their latest research and market trends.

According to 8 analysts, BCAX has a Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicara Therapeutics Inc (BCAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.